This month’s collaborations, tech partnerships, new facilities, and other happenings includes news from Flywheel, Medable, Veeva, and other organizations.
According to an expert from the clinical insights company, prejudice in AI can impact patient outcomes as well as the ability to develop effective treatments.
The pharmaceutical company has announced GMP-related challenges with a manufacturer contracted to fill syringes for Wegovy pens headed to the US market.
The company has released a survey of cancer doctors; 83% of those polled believe real-world data is crucial to accelerating cancer research and treatment.
Professionals from various corners of the life-sciences field share views on significant challenges of 2021, bright spots, and what to look for in 2022.
While the pandemic saw many trials to shift to decentralized midstream, an expert from the trial tech firm suggests a ground-up design approach is preferable.
A leader from the company discusses how advanced analytical tools can be put to work to help tackle adverse event case processing and compliance issues.
A leader from the R&D tech provider discusses the obstacles faced by drug development professionals in recent months, and ways they rose to the occasion.
A leader from the information technology specialist explains how evolved thinking and digital transformation are leading to benefits across the industry.
A leader from the Decentralized Trials and Research Alliance offers perspective on the tools, technology, and thinking needed to advance clinical research.
The Parkinson’s Progression Markers Initiative, built using Evidation Health’s research platform, aims to triple enrollment and recruit online participants.
The artificial intelligence-driven drug discovery company has dosed its first healthy volunteer in a trial for a candidate to treat idiopathic pulmonary fibrosis.
The US agency continues to work with industry professionals on vaccines and treatments for the virus, and to wrestle with current and emerging variants.
According to the company, the latest Phase II/III study results show its novel oral treatment candidate is effective in reducing hospitalizations and deaths.
Novartis has introduced its T-Charge platform at ASH 2021, which it says will serve as the foundation for various new investigational CAR-T cell therapies in its pipeline.
The healthcare company has gifted $1m to form a scholarship fund for students headed toward careers in clinical research, with the aim of increasing diversity.
The pharmaceutical company currently has several promising treatments in development for gastroenterological, dermatological, and cardiological conditions.
Memo Therapeutics AG will receive CHF 10.5m (US $11.4m) from the Swiss government to clinically develop a SARS-CoV-2 antibody against COVID-19, allowing it to start Phase 1 studies in Q1, 2022.
A representative shares ways that COVID-19 has impacted the already intricate pharmaceutical supply chain and offers suggestions to stay ahead of the curve.
A leader from the advanced data and artificial intelligence specialist suggests ways to advance data collection through new tools, techniques, and thinking.
Sited in Pennsylvania, the excipients specialist’s new facility reportedly will work toward advancing drug delivery research and boosting speed to market.
According to a leader from Cytoreason, AI isn’t necessarily the best or only tool suited to discover new and novel therapies—it might take a human touch.
According to a leader from the virtual engagement solutions company, gaps in trial communications can be improved with the intelligent use of technology.
A survey on perceptions toward the decentralized clinical trial format, conducted by Climedo, shows the industry is aware of the benefits but faces barriers
A leader from the tabletting equipment specialist suggests keeping up with maintenance and repair can boost manufacturing efficiency and effectiveness.
The organizations have issued an in-depth look on issues impacting inclusivity, why change is needed, and potential solutions for increasing trial diversity.
An expert from the contract research organization discusses the impact decentralized trials have had on the industry, and how that transformation is likely to continue.
This month’s announcements of awards, expansions, name changes, hires, and other news includes items from CPhI, Almac Group, ICON, and other organizations.
The Oxford-GSK Institute of Molecular and Computational Medicine has been created via a five-year collaboration between GlaxoSmithKline and the University of Oxford.
With the release of its new Sight OLO artificial intelligence based blood analyzer, Sight Diagnostics hopes to offer DCTs reliable, easy-to-use testing.
An expert from the decentralized clinical trial solutions provider discusses how the virtual format and technology can help improve study representation.
A leader from the pharmacovigilance solutions firm discusses the ins and outs managing safety documentation and offers advice on how to deal with them.
Leaders from IQVIA and its Q2 Solutions division offer advice on how to deal with mobile teams, home health providers, and other aspects of virtual trials.
A leader from the IT consulting company makes the case for digitization and explains the potenial benefits of bringing an operation into the 21st century.
The biotech firm has presented data from a study that could offer hope to patients with Parkinson’s, Gaucher, Alzheimer’s and other neurodegenerative conditions.
A leader from Sema4, the health intelligence company, explains how progress in genetic testing has helped advance breast cancer detection and prevention.
A new clinical trial of heterologous – or ‘mix-and-match’ – combinations of COVID-19 vaccines is set to start in Pakistan: seeking to add to research on the effectiveness of such combinations.
Leaders from the trial tech provider discuss how human-focused technology on eClinical platforms can tackle inefficiencies associated with traditional studies.
The alliance is aimed at expanding service to pharmaceutical firms and other partners, and advancing treatment options for patients across North America.
The US agency has granted approval to Voxzogo, an injectable drug designed to aid growth in children with achondroplasia, the most common form of dwarfism.
The StudyTeam Diversity Reporting feature is intended to aid sites and sponsors measure their efforts to reach patients from underrepresented communities.
This month’s launches, expanded facilities, partnerships, and other news includes items from Veeva, Hovione, Florence, Medidata, and other notable firms.
According to data released by the company, the majority of study professionals plan to run agile or hybrid trials over the course of the next 12 months.
According to the pharma firm, Saphnelo (anifrolumab) combined with standard therapy resulted in reduction of systemic lupus erythematosus disease activity.
CRISPR Therapeutics and ViaCyte, Inc. have received the green light from Health Canada for their Clinical Trial Application for VCTX210: an allogeneic, gene-edited, immune-evasive, stem cell-derived therapy for the treatment of type 1 diabetes (T1D)....
The pact between the drug firm and the group is aimed at giving equitable access to treatments and vaccines for people in disadvantaged parts of the world.
The firm is investigating viability of voriconazole inhalation powder, intended to treat and prevent invasive pulmonary aspergillosis in asthma patients.
The pharma company has completed enrollment of amyotrophic lateral sclerosis patients in its study investigating drugs like verdiperstat, an oral treatment.
Johnson & Johnson has announced its intent to separate its Consumer Health business into a new publicly traded company: allowing J&J to put a sharpened focus on pharmaceuticals and medical devices.
